Efforts to find effective treatments for blood cancers extend around the world. Dr Helen Heslop from Baylor College of Medicine and Texas Children’s Hospital will speak at the VCCC Research Conference on Monday 16 September on the development of revolutionary new cancer therapies. Her immunotherapy research directly impacts patients with blood cancers; Dr Heslop is also a haematologist.
Dr Heslop has received high-level recognition for her work in adoptive T cell and immunotherapy and her discoveries have led to improved outcomes for patients with hematopoietic stem cell transplantation and cancer therapy. With her colleagues in Houston, Dr Heslop is working to develop widely applicable targeted cellular therapies for leukemia and lymphoma.
The goal is to improve on past successes in developing targeted cellular therapies, to enable treatments to become the standard of care for a broad range of blood cancers. The research group will develop and implement first-in-person studies with the potential to become clinically effective adoptive cell therapies for diseases that currently lack options, such as non-Hodgkin’s lymphoma, myeloma, and acute myeloid leukemia (AML).
Dr Heslop’s presentation is part of the session titled, Finding the X Factor: maximizing the impact of immunotherapy, chaired by Professor Jonathan Cebon, Olivia Newton-John Cancer Research Institute.
She will be joined by Nicole O’Leary and Professor Sherene Loi from Peter Mac, as well as Dr Oliver Klein from ONJCRI, to discuss advances and obstacles, efficacy of immune checkpoint inhibitors and novel strategies.
Health professionals in the cancer field from across the state and Australia will be attending the VCCC Research Conference 2019 – The Next Wave on Monday 16 and Tuesday 17 September at Sofitel Melbourne on Collins. Read more and register.
